Document Detail


Lipid lowering therapy in atherosclerosis.
MedLine Citation:
PMID:  15861316     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Dyslipidemia plays critical roles in the pathogenesis of coronary atherosclerosis, a chronic inflammatory disease. Vascular inflammation also triggers the onset of acute complications of atherosclerosis, such as myocardial infarction. Advances in cardiovascular medicine demonstrate that lipid-lowering therapy by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) likely prevents acute coronary complications by limiting vascular inflammation. In particular, recent clinical evidence indicates aggressive lipid-lowering treatment for patients at risk. Preclinical studies also support the concept of anti-inflammatory properties of lipid lowering by either diet or statins. Therefore, dyslipidemia is the primary target of therapy for the prevention of coronary atherosclerosis and its acute thrombotic complications. Nevertheless, even aggressive statin therapy does not forestall many adverse events. Thus, current cardiovascular medicine also seeks mechanisms to mitigate vascular inflammation and atherosclerosis other than addressing low-density lipoprotein, and new therapeutic strategies beyond lipid lowering.
Authors:
Masanori Aikawa; Peter Libby
Related Documents :
17338996 - Double-blind, randomized, placebo-controlled study of high-dose hmg coa reductase inhib...
9843466 - Usefulness of electron beam tomography in adolescents and young adults with heterozygou...
19837406 - Association of the single nucleotide polymorphism rs599839 in the vicinity of the sorti...
16674356 - Lipoproteins and cardiovascular disease: biological basis and epidemiological studies.
16426396 - A feasible approach for direct his-bundle pacing using a new steerable catheter to faci...
9894926 - Early angiotensin converting enzyme inhibitor therapy after experimental myocardial inf...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Seminars in vascular medicine     Volume:  4     ISSN:  1528-9648     ISO Abbreviation:  Semin Vasc Med     Publication Date:  2004 Nov 
Date Detail:
Created Date:  2005-04-29     Completed Date:  2005-08-18     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  100940307     Medline TA:  Semin Vasc Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  357-66     Citation Subset:  IM    
Affiliation:
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA, 02155, USA
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Arteriosclerosis / blood,  drug therapy*,  etiology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hyperlipidemias / blood,  complications,  drug therapy
Lipids / blood*
Grant Support
ID/Acronym/Agency:
P01 HL 48743/HL/NHLBI NIH HHS; P50 HL 56985/HL/NHLBI NIH HHS; R01 HL 66086/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Lipids

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Statins and endothelial dysfunction.
Next Document:  Statins and hypertension.